Clinicopathological correlations of cyclooxygenase-2, MDM2, and p53 expressions in surgically resectable pancreatic invasive ductal adenocarcinoma

Pancreas

Volumn 38, Issue 5, 2009, Pages 565-571

  Hermanova, Marketa ^a   Karasek, Petr ^b   Nenutil, Rudolf ^b   Kyr, Michal ^c   Tomasek, Jiri ^d   Baltasova, Ivana ^a   Dite, Petr ^d  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

COX 2; Grade; MDM2; p53; Pancreatic cancer; Prognostic factor

Indexed keywords

CYCLOOXYGENASE 2; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CORRELATIONAL STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67651093948     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31819fef8b     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Path. 2001;25:579-586. (Pubitemid 32423354)
3. Hruban RH,Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol. 2000;156:1821-1825.
4. Farrow B, Sugiyama Y, Chen A, et al. Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg. 2004;239: 763-771. (Pubitemid 38669427)
5. Garcea G, Dennison AR, Steward WP, et al. Role of the inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology. 2005;5:514-529. (Pubitemid 41407282)
6. Farrow B, Evers BM. Inflammation and the development of pancreatic cancer. Surg Oncol. 2002;10:153-169.
7. Tanabe T, Tohnai N. Cyclooxygenase isoenzymes and their gene structures and expression. Prostaglandins Other Lipid Mediat. 2002; 68-69:95-114.
8. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci. 2000;37:431-502. (Pubitemid 32173442)
9. Williams CS, Mann M, Dubios RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18: 7908-7916. (Pubitemid 30066236)
10. Dannenberg AJ, Altorki NK, Boyle JO, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001;2:544-551. (Pubitemid 33586867)
11. Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential chemoprevention by cyclooxygenase inhibitors. Cancer. 2001;91: 333-338. (Pubitemid 32099234)
12. Albazaz R, Verbeke CS, Rahman SH, et al. Cyclooxygenase-2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer. Pancreatology. 2005;5:361-369. (Pubitemid 41160273)
13. Maitra A, Ashfaq R, Gunn CR, et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia. Am J Clin Pathol. 2002;118:194-201.
14. Hermanova M, Trna J, Nenutil R, et al. Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignanat ductal pancreatic lesions. Eur J Gastroenterol Hepatol. 2008;20: 732-739.
15. Chu J, Lloyd FL, Trifan OC, et al. Potential involvement of cyclooxygenase-2 pathway in the regulation of tumor associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther. 2003;2:1-7.
16. Kong G, Kim EK, Kim WS, et al. Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepatol. 2002;17:914-921.
17. Ding XZ, Tong WG, Adrian TE. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res. 2000;20:2625-2631.
18. Eibl G, Bruemmer D, Okada Y, et al. PGE (2) is generated by specific COX-2 activity and increases VEGF production in COX-2 expressing human pancreatic cancer cells. Biochem Biophys Res Commun. 2003;306:887-897.
19. Hofseth LJ, Hussain SP, Harris CC. p53: 25 years after its discovery. Trends Pharmacol Sci. 2004;25:177-181.
20. Prives C, Hall PA. The p53 pathway. J Pathol. 1999;187:112-126.
21. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
22. Lane DP, Hall PA. MDM2 - arbiter of p53's destruction. Trends Biochem Sci. 1997;22:372-374.
23. O'Hagan HM, Ljungman M. Nuclear accumulation of p53 following inhibition of transcription is not due to diminished levels of MDM2. Oncogene. 2004;23:5505-5512. (Pubitemid 39044061)
24. Inoue T, Wu L, Stuart J, et al. Control of nuclear accumulation in stressed cells. FEBS Lett. 2005;22:4978-4984.
25. Hollstein M, Sidranski D, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991;253:49-53.
26. Barton CM, Staddon SL, Hughes CM, et al. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br J Cancer. 1991;64:1076-1082.
27. Hruban RH, Yeo CJ, Kern SE. The genetic basis of human cancer. In: Vogelstein B, Kinzler KW, eds. Pancreatic Cancer. New York, NY: McGraw-Hill; 1996:603-613.
28. Bartek J, Bartkova J, Lukas Z, et al. Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol. 1993;169:27-34. (Pubitemid 23034420)
29. Nenutil R, Smardova J, Pavlova S, et al. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol. 2005;207:251-259. (Pubitemid 41556448)
30. Corcoran CA, He Q, Huang Y, et al. Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis. Oncogene. 2005;24:1634-1640. (Pubitemid 40396093)
31. Han JA, Kim JI, Ongusaha PP, et al. P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J. 2002;21:5635-5644.
32. Subbaramaiah K, Altorki N, Chung WJ, et al. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem. 1999;274: 10911-10915. (Pubitemid 129528294)
33. Benoit V, de Moraes E, Dar NA, et al. Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappa B. Oncogene. 2006;25:5708-5718. (Pubitemid 44435248)
34. de Moraes E, Dar NA, de Moura Gallo CV, et al. Cross talk between cyclooxygenase-2 and tumor suppressor protein p53: balancing life and death during inflammatory stress and carcinogenesis. Int J Cancer. 2007;121:929-937.
35. Dong M, Ma G, TuW, et al. Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer. World J Gastroenterol. 2005;11:2162-2165. (Pubitemid 40542663)
36. Soussi T, Beroud S. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001;1:233-240. (Pubitemid 33741898)
37. Petitjean A, Achatz MI, Borresen-Dale AL, et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26:2157-2165. (Pubitemid 46536647)
38. Nio Y, Dong M, Uegaki K, et al. Comparative significance of p53 and WAF/1-p21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas. Pancreas. 1999;18:117-126. (Pubitemid 29180107)
39. Nio Y, Dong M, Iguchi C, et al. Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy. J Surg Oncol. 2001;76:188-196. (Pubitemid 32240229)
40. Sato Y, Nio Y, Song M, et al. p53 protein expression as prognostic factor in human pancreatic cancer. Anticancer Res. 1997;17:2779-2788. (Pubitemid 27352687)
41. Nakamori S, Yashima K, Murakami Y, et al. Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J Cancer Res. 1995;86:174-181.
42. Molina MA, Sitja-Arnau M, Lemoine MG, et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999;59:4356-4362. (Pubitemid 29418754)
43. Yip-Schneider MT, Sweeney CJ, Jung SH, et al. Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J Pharmacol Exp Ther. 2001;298:976-985.
44. Juuti A, Louhimo J, Nordling S, et al. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol. 2006;59:382-386.
45. Matsubayashi H, Infante JR, Winter J, et al. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biol Ther. 2007;6:1569-1575. (Pubitemid 351590328)
46. Koshiba T, Hosotani R, Miyamoto Y, et al. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol. 1999;26:69-76.
47. Merati K, Siadaty M, Andea A, et al. Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathological and clinical parameters. Am J Clin Oncol. 2001;24:447-452. (Pubitemid 32959100)
48. Matsumoto G, Muta M, Tsuruta K, et al. Tumor size significantly correlates with postoperative liver metastases and COX-2 expression in patients with resectable pancreatic cancer. Pancreatology. 2007;7:167-173. (Pubitemid 47094086)